11/21
01:30 pm
jazz
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer [Yahoo! Finance]
Low
Report
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer [Yahoo! Finance]
11/21
12:57 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
11/21
08:59 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock, down previously from $166.00.
Low
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $163.00 price target on the stock, down previously from $166.00.
11/21
06:07 am
jazz
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) [Yahoo! Finance]
Low
Report
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) [Yahoo! Finance]
11/20
07:22 pm
jazz
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) [Yahoo! Finance]
Medium
Report
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) [Yahoo! Finance]
11/20
07:19 pm
jazz
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Medium
Report
Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
11/20
08:57 am
jazz
VMS BioMarketing Changes its Name to Momentum Life Sciences, Reinforcing its Commitment to Patient Engagement [Yahoo! Finance]
Low
Report
VMS BioMarketing Changes its Name to Momentum Life Sciences, Reinforcing its Commitment to Patient Engagement [Yahoo! Finance]
11/19
04:11 pm
jazz
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference [Yahoo! Finance]
11/19
04:05 pm
jazz
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
11/19
04:05 pm
jazz
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference
11/19
10:51 am
jazz
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock? [Yahoo! Finance]
Low
Report
Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock? [Yahoo! Finance]
11/19
08:41 am
jazz
Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment [Yahoo! Finance]
Low
Report
Silver Ring Value Partners: Jazz Pharmaceuticals (JAZZ) Is a “High Uncertainty With Low Risk” Investment [Yahoo! Finance]
11/18
08:35 am
jazz
Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now? [Yahoo! Finance]
Medium
Report
Is Jazz Pharmaceuticals plc (JAZZ) the Best Immunotherapy Stock to Buy Now? [Yahoo! Finance]
11/18
08:07 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Robert W. Baird from $154.00 to $162.00. They now have an "outperform" rating on the stock.
Medium
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Robert W. Baird from $154.00 to $162.00. They now have an "outperform" rating on the stock.
11/14
10:27 am
jazz
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock? [Yahoo! Finance]
Low
Report
Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock? [Yahoo! Finance]
11/14
06:52 am
jazz
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest [Yahoo! Finance]
Low
Report
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Performance Is Even Better Than Its Earnings Suggest [Yahoo! Finance]
11/13
01:26 pm
jazz
Jazz (JAZZ) Upgraded to Buy: Here's Why [Yahoo! Finance]
Low
Report
Jazz (JAZZ) Upgraded to Buy: Here's Why [Yahoo! Finance]
11/13
01:26 pm
jazz
JAZZ or CTLT: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Low
Report
JAZZ or CTLT: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
11/13
11:16 am
jazz
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High? [Yahoo! Finance]
11/11
10:47 am
jazz
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know [Yahoo! Finance]
Low
Report
Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know [Yahoo! Finance]
11/7
04:11 pm
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at TD Cowen from $200.00 to $195.00. They now have a "buy" rating on the stock.
Medium
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target lowered by analysts at TD Cowen from $200.00 to $195.00. They now have a "buy" rating on the stock.
11/7
12:35 pm
jazz
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View [Yahoo! Finance]
Low
Report
Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View [Yahoo! Finance]
11/7
08:36 am
jazz
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
Medium
Report
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $207.00 price target on the stock.
11/7
02:31 am
jazz
Jazz Pharmaceuticals PLC (JAZZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Jazz Pharmaceuticals PLC (JAZZ) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
11/6
08:28 pm
jazz
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]
Medium
Report
Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key Metrics [Yahoo! Finance]